Severe eosinophilic asthma: A roadmap to consensus

European Respiratory Journal

Volumn 49, Issue 5, 2017, Pages

  Buhl, Roland ^a   Humbert, Marc ^b   Bjermer, Leif ^c   Chanez, Pascal ^d   Heaney, Liam G ^e   Pavord, Ian ^f   Quirce, Santiago ^g   Virchow, Johann C ^h   Holgate, Stephen ⁱ   Djukanovic, Ratko ⁱ   Chung, Kian Fan ^j   Canonica, Walter ^k   Papi, Alberto ^l   Brightling, Chris ^m   Horváth, Ildiko ⁿ   Walker, Samantha ^o   Brusselle, Guy ^p   Backer, Vibeke ^q   Kuna, Piotr ^r   Bel, Elisabeth ^s   De Llano, Luis Perez ^t   Rabe, Klaus ^u   more..

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d AIX MARSEILLE UNIVERSITY   (France)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h UNIVERSITY OF ROSTOCK   (Germany)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k HUMANITAS UNIVERSITY   (Italy)

^l UNIVERSITY OF FERRARA   (Italy)

^m UNIVERSITY OF LEICESTER   (United Kingdom)

ⁿ SEMMELWEIS UNIVERSITY   (Hungary)

^o ASTHMA UK   (United Kingdom)

^p GHENT UNIVERSITY HOSPITAL   (Belgium)

^q BISPEBJERG HOSPITAL   (Denmark)

^r UNIVERSITY OF LODZ   (Poland)

^s UNIVERSITY OF AMSTERDAM   (Netherlands)

^t Hospital Universitario Lucus Agusti   (Spain)

^u UNIVERSITY OF KIEL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENRALIZUMAB; CORTICOSTEROID; DUPILUMAB; MEPOLIZUMAB; OMALIZUMAB; PITRAKINRA; RESLIZUMAB; TRALOKINUMAB; BIOLOGICAL FACTOR;

ASTHMA; CONSENSUS; DISEASE EXACERBATION; EOSINOPHIL; EOSINOPHILIA; FOLLOW UP; HUMAN; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SEVERE EOSINOPHILIC ASTHMA; DISEASE MANAGEMENT; EUROPE; LOEFFLER PNEUMONIA; MEDICAL SOCIETY; SEVERITY OF ILLNESS INDEX;

ASTHMA; BIOLOGICAL FACTORS; CONSENSUS; DISEASE MANAGEMENT; EUROPE; HUMANS; PULMONARY EOSINOPHILIA; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL;

EID: 85019110286     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00634-2017     Document Type: Review

References (26)

1. Corren J. Asthma phenotypes and endotypes: an evolving paradigm for classification. Discov Med 2013; 15: 243-249.
2. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47: 410-419.
3. Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet 2015; 386: 1086-1096.
4. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-373.
5. de Groot JC, ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res 2015; 1: 00024-2015.
6. Castro M, Bacharier LB. Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies? Lancet 2016; 388: 2059-2060.
7. Schleich FN, Chevremont A, Paulus V, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 2014; 44: 97-108.
8. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388: 2115-2127.
9. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3: 355-366.
10. Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016; 4: 549-556.
11. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
12. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388: 2128-2141.
13. Bel EH, Ortega HG, Pavord ID. Glucocorticoids and mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 2433-2434.
14. Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 2016; 150: 799-810.
15. Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 2016; 150: 789-798.
16. Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015; 135: 896-902.
17. de Groot JC, Storm H, Amelink M, et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res 2016; 2: 00100-2015.
18. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-224.
19. Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015; 3: 849-858.
20. Arbes SJ Jr. Do all asthmatics with atopy have atopic asthma? J Allergy Clin Immunol 2012; 130: 1202-1204.
21. Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015; 70: 115-120.
22. Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2: 879-890.
23. Froidure A, Mouthuy J, Durham SR, et al. Asthma phenotypes and IgE responses. Eur Respir J 2016; 47: 304-319.
24. Brandström J, Vetander M, Lilja G, et al. Individually dosed omalizumab: an effective treatment for severe peanut allergy. Clin Exp Allergy 2017; 47: 540-550.
25. Konradsen JR, Nordlund B, Nilsson OB, et al. High basophil allergen sensitivity (CD-sens) is associated with severe allergic asthma in children. Pediatr Allergy Immunol 2012; 23: 376-384.
26. Cabon Y, Molinari N, Marin G, et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy 2017; 47: 129-138.